568 related articles for article (PubMed ID: 35955549)
1. Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.
van Schaik PEM; Zuhorn IS; Baron W
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955549
[TBL] [Abstract][Full Text] [Related]
2. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
Stoffels JM; de Jonge JC; Stancic M; Nomden A; van Strien ME; Ma D; Sisková Z; Maier O; Ffrench-Constant C; Franklin RJ; Hoekstra D; Zhao C; Baron W
Brain; 2013 Jan; 136(Pt 1):116-31. PubMed ID: 23365094
[TBL] [Abstract][Full Text] [Related]
3. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
Qin J; Sikkema AH; van der Bij K; de Jonge JC; Klappe K; Nies V; Jonker JW; Kok JW; Hoekstra D; Baron W
J Neurosci; 2017 Oct; 37(41):9925-9938. PubMed ID: 28899916
[TBL] [Abstract][Full Text] [Related]
4. MMP7 cleaves remyelination-impairing fibronectin aggregates and its expression is reduced in chronic multiple sclerosis lesions.
Wang P; Gorter RP; de Jonge JC; Nazmuddin M; Zhao C; Amor S; Hoekstra D; Baron W
Glia; 2018 Aug; 66(8):1625-1643. PubMed ID: 29600597
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of the interstitial extracellular matrix in white matter multiple sclerosis lesions: Implications for remyelination (failure).
de Jong JM; Wang P; Oomkens M; Baron W
J Neurosci Res; 2020 Jul; 98(7):1370-1397. PubMed ID: 31965607
[TBL] [Abstract][Full Text] [Related]
6. Lesion stage-dependent causes for impaired remyelination in MS.
Heß K; Starost L; Kieran NW; Thomas C; Vincenten MCJ; Antel J; Martino G; Huitinga I; Healy L; Kuhlmann T
Acta Neuropathol; 2020 Sep; 140(3):359-375. PubMed ID: 32710244
[TBL] [Abstract][Full Text] [Related]
7. The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis.
Ghorbani S; Yong VW
Brain; 2021 Aug; 144(7):1958-1973. PubMed ID: 33889940
[TBL] [Abstract][Full Text] [Related]
8. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis.
Motavaf M; Sadeghizadeh M; Javan M
Cell Mol Neurobiol; 2017 Nov; 37(8):1335-1348. PubMed ID: 28224237
[TBL] [Abstract][Full Text] [Related]
9. Multiple Sclerosis: Basic and Clinical.
Buzzard K; Chan WH; Kilpatrick T; Murray S
Adv Neurobiol; 2017; 15():211-252. PubMed ID: 28674983
[TBL] [Abstract][Full Text] [Related]
10. Myelin regulatory factor drives remyelination in multiple sclerosis.
Duncan GJ; Plemel JR; Assinck P; Manesh SB; Muir FGW; Hirata R; Berson M; Liu J; Wegner M; Emery B; Moore GRW; Tetzlaff W
Acta Neuropathol; 2017 Sep; 134(3):403-422. PubMed ID: 28631093
[TBL] [Abstract][Full Text] [Related]
11. Signaling mechanisms involved in the regulation of remyelination in multiple sclerosis: a mini review.
Devanand M; V N S; Madhu K
J Mol Med (Berl); 2023 Jun; 101(6):637-644. PubMed ID: 37084092
[TBL] [Abstract][Full Text] [Related]
12. Endogeneous remyelination: findings in human studies.
Kipp M; Victor M; Martino G; Franklin RJ
CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):598-609. PubMed ID: 22583436
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination.
Shen K; Reichelt M; Kyauk RV; Ngu H; Shen YA; Foreman O; Modrusan Z; Friedman BA; Sheng M; Yuen TJ
Cell Rep; 2021 Mar; 34(10):108835. PubMed ID: 33691116
[TBL] [Abstract][Full Text] [Related]
14. [Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy].
Nakahara J
Rinsho Shinkeigaku; 2012; 52(11):1351-3. PubMed ID: 23196615
[TBL] [Abstract][Full Text] [Related]
15. The extracellular matrix: Focus on oligodendrocyte biology and targeting CSPGs for remyelination therapies.
Pu A; Stephenson EL; Yong VW
Glia; 2018 Sep; 66(9):1809-1825. PubMed ID: 29603376
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis.
Zhao X; Jacob C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047344
[TBL] [Abstract][Full Text] [Related]
17. Myelination in Multiple Sclerosis Lesions Is Associated with Regulation of Bone Morphogenetic Protein 4 and Its Antagonist Noggin.
Harnisch K; Teuber-Hanselmann S; Macha N; Mairinger F; Fritsche L; Soub D; Meinl E; Junker A
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609838
[TBL] [Abstract][Full Text] [Related]
18. Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions.
Pfeifenbring S; Metz I; Kremer D; Küry P; Hartung HP; Brück W
Glia; 2013 Aug; 61(8):1250-60. PubMed ID: 23828667
[TBL] [Abstract][Full Text] [Related]
19. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
Keirstead HS; Blakemore WF
Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis - remyelination failure as a cause of disease progression.
Hagemeier K; Brück W; Kuhlmann T
Histol Histopathol; 2012 Mar; 27(3):277-87. PubMed ID: 22237705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
